In the Media
GeneTherapyLive: Non-Viral Gene Therapy Eases Treatment Burden in Wet AMD 150 150 Eyevensys

GeneTherapyLive: Non-Viral Gene Therapy Eases Treatment Burden in Wet AMD

A non-viral gene therapy sustained drug-delivery product that delivers anti-VEGF to the eye may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients with wet AMD.

Can Gene Therapy Cure Blindness? 150 150 Eyevensys

Can Gene Therapy Cure Blindness?

LABIOTECH.eu reports on Eyevensys and other innovative companies developing gene therapy treatments with the potential to cure different forms of genetic blindness.

Women Worldwide Podcast: How Are You Innovating in Your Role? 150 150 Eyevensys

Women Worldwide Podcast: How Are You Innovating in Your Role?

Eyevensys CEO, Patricia Zilliox, discusses innovation as a key component of growth in the medical and pharmaceutical industry, what her work has taught her about fundraising, and the impact of the pandemic on her work.

OIS: Francine Behar-Cohen Presents “Innovative Non-Viral Therapies for the Treatment of Ocular Diseases” 150 150 Eyevensys

OIS: Francine Behar-Cohen Presents “Innovative Non-Viral Therapies for the Treatment of Ocular Diseases”

Watch Eyevensys Founder and Chief Innovation Officer, Prof. Francine Behar-Cohen, present at the OIS Ocular Drug Delivery Meeting, providing details about our innovative non-viral gene therapies for the treatment of ocular diseases and our active pipeline and strategy.

Le Figaro: Eyevensys, the Ray of Hope for Treating Ophthalmological Diseases 150 150 Eyevensys

Le Figaro: Eyevensys, the Ray of Hope for Treating Ophthalmological Diseases

Eyevensys founder, Francine Behar-Cohen, and Scientific Director, Thierry Bordet talk to Le Figaro about the company’s innovative treatments and technology in development for treating eye diseases. (article and video)

OIS: Eyevensys CEO, Patricia Zilliox, Featured on OIS Retina Podcast 150 150 Eyevensys

OIS: Eyevensys CEO, Patricia Zilliox, Featured on OIS Retina Podcast

Listen to Patricia Zilliox, CEO of Eyevensys, discuss her background, her industry experience and expertise, and her passion for developing treatments to improve patient outcomes.

Labiotech: Why a US Presence Can Help European Biotechs Get Ahead 150 150 Eyevensys

Labiotech: Why a US Presence Can Help European Biotechs Get Ahead

Patricia Zilliox, CEO of Eyevensys, discusses building the company’s presence in the US.

Labiotech: Eyevensys’ Gene Therapy for Blindness Boosted with €27M Series B 150 150 Eyevensys

Labiotech: Eyevensys’ Gene Therapy for Blindness Boosted with €27M Series B

Patricia Zilliox, CEO of Eyevensys speaks about raising €27M to fund the launch of a phase II trial for its lead candidate, a non-viral gene therapy for an eye condition called uveitis that can lead to blindness.

Healio: Eyevensys closes on $30 million Series B financing 150 150 Eyevensys

Healio: Eyevensys closes on $30 million Series B financing

Patricia Zilliox, CEO of Eyevensys discusses closing a $30 million in Series B financing intended for development of EYS606 for the treatment of chronic noninfectious uveitis.

Dallas News: Paris and Fort Worth-based biotech company Eyevensys raises $30 million to develop treatments for eye diseases 150 150 Eyevensys

Dallas News: Paris and Fort Worth-based biotech company Eyevensys raises $30 million to develop treatments for eye diseases

Patricia Zilliox, CEO of Eyevensys discusses next steps for the company after completing a series B financing round.

  • 1
  • 2